Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CJ-13,610 is an orally active and nonredox-type inhibitor of 5-lipoxygenase (5-LOX). CJ-13,610 inhibits the biosynthesis of leukotriene B4 and regulates the expression of IL-6 mRNA in macrophages.
Description | CJ-13,610 is an orally active and nonredox-type inhibitor of 5-lipoxygenase (5-LOX). CJ-13,610 inhibits the biosynthesis of leukotriene B4 and regulates the expression of IL-6 mRNA in macrophages. |
In vitro | CJ-13,610 dose-dependently suppresses 5-LOX product formation in ionophore A23187-stimulated polymorphonuclear in the absence of exogenous arachidonic acid with an IC50 of about 70 nM[1]. |
Synonyms | CJ 13610, CJ-13610 |
Molecular Weight | 393.5 |
Formula | C22H23N3O2S |
CAS No. | 179420-17-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CJ-13,610 179420-17-8 Metabolism Lipoxygenase CJ13610 CJ 13610 inhibit CJ 13,610 LOX nonredox-type polymorphonuclear leukocytes Inhibitor arachidonic acid CJ-13610 CJ13,610 inhibitor